Procedures for fetal neuroprotection: use of magnesium sulfate.
暂无分享,去创建一个
[1] Caroline A Crowther,et al. Magnesium sulphate at 30 to 34 weeks’ gestational age: neuroprotection trial (MAGENTA) - study protocol , 2013, BMC Pregnancy and Childbirth.
[2] C. Crowther,et al. Magnesium sulphate for women at term for neuroprotection of the fetus. , 2013, The Cochrane database of systematic reviews.
[3] J. Fullerton,et al. An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management , 2013, BMC Pregnancy and Childbirth.
[4] Patient safety checklist No. 7: magnesium sulfate before anticipated preterm birth for neuroprotection. , 2012, Obstetrics and gynecology.
[5] A. Synnes,et al. SOGC Clinical Practice Guideline. Magnesium sulphate for fetal neuroprotection. , 2011, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.
[6] O. Luria,et al. Effect of vaginal progesterone, administered to prevent preterm birth, on impedance to blood flow in fetal and uterine circulation , 2010, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.
[7] Jagjit Singh,et al. Magnesium for neuroprotection in birth asphyxia , 2010, Journal of pediatric neurosciences.
[8] R. Bittar,et al. Indicadores de risco para o parto prematuro , 2009 .
[9] M. Zugaib,et al. [Risk predictors for preterm birth]. , 2009, Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia.
[10] L. Doyle,et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. , 2009, The Cochrane database of systematic reviews.
[11] K. Nelson,et al. Magnesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. , 2000, American journal of obstetrics and gynecology.
[12] J. Canterino,et al. Maternal magnesium sulfate and the development of neonatal periventricular leucomalacia and intraventricular hemorrhage. , 1999, Obstetrics and gynecology.
[13] G. Thurnau,et al. The effect of maternal magnesium sulfate treatment on neonatal morbidity in < or = 1000-gram infants. , 1998, American journal of perinatology.
[14] C. Shen,et al. Effect of magnesium sulfate on the development of cystic periventricular leukomalacia in preterm infants. , 1997, American journal of perinatology.
[15] C. Berg,et al. Prenatal Magnesium Sulfate Exposure and the Risk for Cerebral Palsy or Mental Retardation Among Very Low-Birth-Weight Children Aged 3 to 5 Years , 1996 .
[16] K. Nelson,et al. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? , 1995, Pediatrics.